1656 related articles for article (PubMed ID: 27375156)
1. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
2. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
Dunbar EM; Buzzeo MP; Levine JB; Schold JD; Meier-Kriesche HU; Reddy V
Haematologica; 2008 Dec; 93(12):1852-8. PubMed ID: 18945751
[TBL] [Abstract][Full Text] [Related]
3. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
5. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
[TBL] [Abstract][Full Text] [Related]
6. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
7. Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome.
Hattori N; Saito B; Sasaki Y; Shimada S; Murai S; Abe M; Baba Y; Watanuki M; Fujiwara S; Kawaguchi Y; Arai N; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Harada H; Nakamaki T
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1841-1847. PubMed ID: 29753837
[TBL] [Abstract][Full Text] [Related]
8. Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
Yeral M; Kasar M; Boga C; Kozanoglu I; Ozdogu H; Sariturk C
Exp Clin Transplant; 2015 Oct; 13(5):453-60. PubMed ID: 26103468
[TBL] [Abstract][Full Text] [Related]
9. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
10. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
Park BG; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH
Leuk Res; 2015 Dec; 39(12):1334-41. PubMed ID: 26422556
[TBL] [Abstract][Full Text] [Related]
11. Enumeration of bone marrow plasmacytoid dendritic cells by multiparameter flow cytometry as a prognostic marker following allogeneic hematopoietic stem cell transplantation.
Su RJ; Green R; Chen M
Blood Cells Mol Dis; 2018 Mar; 69():107-112. PubMed ID: 29137845
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.
Klyuchnikov E; Asenova S; Kern W; Kilinc G; Ayuk F; Wiedemann B; Lioznov M; Freiberger P; Zalyalov Y; Zander AR; Kröger N; Bacher U
Leuk Lymphoma; 2010 Aug; 51(8):1450-63. PubMed ID: 20557144
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
14. Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation.
Ando T; Tachibana T; Tanaka M; Suzuki T; Ishiyama Y; Koyama S; Ogusa E; Numata A; Matsumoto K; Kanamori H; Nakajima H
Blood Adv; 2020 Jan; 4(2):408-419. PubMed ID: 31990335
[TBL] [Abstract][Full Text] [Related]
15. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.
Abdel-Azim H; Elshoury A; Mahadeo KM; Parkman R; Kapoor N
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1437-1446. PubMed ID: 28495643
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide.
Greco R; Lorentino F; Nitti R; Lupo Stanghellini MT; Giglio F; Clerici D; Xue E; Lazzari L; Piemontese S; Mastaglio S; Assanelli A; Marktel S; Corti C; Bernardi M; Ciceri F; Peccatori J
Front Immunol; 2019; 10():2319. PubMed ID: 31632401
[No Abstract] [Full Text] [Related]
17. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.
Murashige N; Kami M; Kishi Y; Kim SW; Takeuchi M; Matsue K; Kanda Y; Hirokawa M; Kawabata Y; Matsumura T; Kusumi E; Hirabayashi N; Nagafuji K; Suzuki R; Takeuchi K; Oshimi K
Br J Haematol; 2005 Aug; 130(4):561-7. PubMed ID: 16098071
[TBL] [Abstract][Full Text] [Related]
18. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
Kheav VD; Busson M; Scieux C; Peffault de Latour R; Maki G; Haas P; Mazeron MC; Carmagnat M; Masson E; Xhaard A; Robin M; Ribaud P; Dulphy N; Loiseau P; Charron D; Socié G; Toubert A; Moins-Teisserenc H
Haematologica; 2014 Dec; 99(12):1860-7. PubMed ID: 25085354
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.
Rueff J; Medinger M; Heim D; Passweg J; Stern M
Biol Blood Marrow Transplant; 2014 Jun; 20(6):896-9. PubMed ID: 24631739
[TBL] [Abstract][Full Text] [Related]
20. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
